OGEN
ORAGENICS INC
$0.6000
+1.69%
$2.7M
No data for this timeframe.
Vol
Market Cap$2.7M
Cap SizeNano Cap
Inst. Holders3 funds
Inst. Value$164.00
Inst. Activity0 buys / 3 sells
SEC Reports6
Press Releases2
Recent Activity
May 20, 2026
SEC
Oragenics Inc filed a DEFA14A (definitive additional proxy soliciting materials) on May 20, 2026. The filing is related
DEFA14A — Impact 6/10
May 19, 2026
SEC
Oragenics filed an 8-K with a shareholder update and investor presentation ahead of the Sidoti Micro-Cap Conference. The
8-K — Impact 4/10
May 7, 2026
SEC
Oragenics signed a non-binding Letter of Intent to license CardioDialysis, an extracorporeal blood purification technolo
8-K — Impact 4/10
Inst.
UBS Group AG — NEAR_EXIT
271 shares ($355.00)
Inst.
MORGAN STANLEY — NEAR_EXIT
138 shares ($181.00)
May 19, 2026
other
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
<p align="justify"><strong>Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc.
Mar 25, 2026
Press
Oragenics issued a press release to comply with NYSE American rules, confirming that its audited financial statements fo
Impact 7/10
Mar 11, 2026
Press
Oragenics, Inc. announced it is exploring potential acquisitions of CNS-focused assets that align with its proprietary i
Impact 4/10
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Latest Reports
NEUTRAL
DEFA14A
6/10
Oragenics Inc filed a DEFA14A (definitive additional proxy soliciting materials) on May 20, 2026. The filing is related
May 20, 2026
NEUTRAL
8-K
4/10
Oragenics filed an 8-K with a shareholder update and investor presentation ahead of the Sidoti Micro-Cap Conference. The
May 19, 2026
BEARISH
Press
7/10
Oragenics issued a press release to comply with NYSE American rules, confirming that its audited financial statements fo
Mar 25, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $108.00 | NEAR_EXIT |
| BANK OF AMERICA CORP | $29.00 | NEAR_EXIT |
| WELLS FARGO & COMPANY/MN | $27.00 | — |
3 institutional holders with $164.00 total value (209 shares) as of 2025-Q4. Top holders: MORGAN, BANK, WELLS.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 138 | $108.00 | 65.9% | NEAR_EXIT -98.8% |
| 2 | BANK OF AMERICA CORP /DE/ | 37 | $29.00 | 17.7% | NEAR_EXIT -99.8% |
| 3 | WELLS FARGO & COMPANY/MN | 34 | $27.00 | 16.5% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | NEAR_EXIT | 1,892 | 271 | -85.7% | $355.00 | 2025-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 11,912 | 138 | -98.8% | $181.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 15,546 | 36 | -99.8% | $47.00 | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 15,546 | — | $59.4K | 2025-Q2 |
| MORGAN STANLEY | NEW | — | 11,912 | — | $45.5K | 2025-Q2 |
| MORGAN STANLEY | DOUBLED | 1,001 | 4,336 | +333.2% | $1.6K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 1 | 1,001 | +100000.0% | $382.00 | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 6 neutral. Avg impact: 4.2/10.
NEUTRAL
DEFA14A
6/10
Oragenics Inc filed a DEFA14A (definitive additional proxy soliciting materials) on May 20, 2026. Th
May 20, 2026
NEUTRAL
8-K
4/10
Oragenics filed an 8-K with a shareholder update and investor presentation ahead of the Sidoti Micro
May 19, 2026
NEUTRAL
8-K
4/10
Oragenics signed a non-binding Letter of Intent to license CardioDialysis, an extracorporeal blood p
May 7, 2026
NEUTRAL
8-K
4/10
Oragenics announced the first patient dosing in its Phase IIa clinical trial for ONP-002, a potentia
Apr 13, 2026
NEUTRAL
EFFECT
4/10
Oragenics Inc. (OGEN) has announced the effectiveness of its shelf registration statement (Form S-3)
Mar 23, 2026
NEUTRAL
8-K
3/10
Analysis based on filing metadata only — document content was unavailable. The filing is an 8-K with
Mar 11, 2026
Historical analyst distribution: 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 19, 2026
other
Oragenics to Present at Sidoti’s Micro-Cap Virtual Investor Conference May 20-21
<p align="justify"><strong>Sarasota, FL, May 19, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Compan
May 18, 2026
other
ORAGENICS PROVIDES INVESTOR UPDATE
<p><b>A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER</b></p>
May 7, 2026
earnings_calendar
OGEN Q1 2026 Earnings Scheduled — 2026-05-07
May 5, 2026
other
Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury.
<p align="justify"><b>SARASOTA, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- </b>Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology com
Apr 13, 2026
other
Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury
<p align="justify"><strong>SARASOTA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- </strong>Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biote
Mar 25, 2026
critical
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
<p align="justify">SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company
Mar 12, 2026
other
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
<p align="center"><b><i>FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA</i></b></p>
Mar 12, 2026
earnings_calendar
OGEN Q4 2025 Earnings After Market Close — 2026-03-12
Mar 11, 2026
m_and_a
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
<p align="justify">SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company
Mar 10, 2026
other
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
<p align="center"><b><i>All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sites</i></b><b